drugset

drugset / Trial / NCT00143416

Long Term Study With B2036-PEG

NCT00143416 ↗

Phase 3 Completed 16 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.

Timeline

Start: 2004-04
Primary completion: —
Completion: 2007-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegvisomant	Protein / enzyme biologic	—	—

Indications